Bio-Rad Reports Mixed 2025 Results with Significant Impairments Offset by Non-Operating Gain and Share Repurchases
BIO sits 21% above its 52-week low of $211.43 on elevated volume (2.1× avg).
Summary
Bio-Rad Laboratories reported a net income of $759.9 million for 2025, a significant improvement from a prior year loss, primarily due to a large non-operating gain from its Sartorius investment, despite flat sales and $172.8 million in impairment charges on acquired R&D assets.
Key Events · Earnings and Guidance · BIO
-
Significant Impairment Charges on Acquired R&D Assets
The company recorded $172.8 million in impairment charges related to in-process research and development (IPR&D) assets. This includes an $81.7 million impairment for the 2021 Dropworks acquisition due to delayed technology and revised forecasts, and a $127.7 million impairment for the 2022 Curiosity Diagnostics acquisition due to development discontinuation. This follows the 8-K disclosure on February 12, 2026, providing full details and context.
-
Net Income Driven by Non-Operating Gain
Bio-Rad reported a net income of $759.9 million ($27.85 diluted EPS) for 2025, a substantial improvement from a $1.84 billion net loss in 2024. This was primarily attributable to a $900.4 million gain from the change in fair market value of its investment in Sartorius AG.
-
Flat Sales and Declining Gross Margins
Net sales for 2025 were $2.58 billion, a modest 0.7% increase, with currency-neutral sales remaining essentially flat. Consolidated gross margin decreased by 1.8 percentage points to 51.9%, impacted by inventory write-offs and higher material costs.
-
Ongoing Share Repurchase Program
The company repurchased $295.5 million of Class A common stock in 2025. As of December 31, 2025, $284.6 million remained available under the $1 billion share repurchase program.
Analysis · BIO · Industrial Applications And Services
Bio-Rad Laboratories' 2025 annual report reveals a complex financial picture. While the company reported a substantial net income turnaround, this was largely driven by a non-operating gain from its investment in Sartorius AG, rather than core operational strength. The significant impairment charges on acquired R&D assets highlight challenges in product development and M&A integration. Investors should note the flat organic revenue growth and declining gross margins, which indicate underlying operational pressures. The ongoing share repurchase program is a positive for shareholder returns, but the overall sentiment remains mixed due to the operational headwinds.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1644 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BIO was trading at $255.00 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $7.9B. The 52-week trading range was $211.43 to $343.12. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.